MeiraGTx Holdings Plc. (MGTX), Wednesday announced that the U.S. Food and Drug Administration has granted the Rare Pediatric Disease Designation to its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis that results in severe vision loss in children.
The clinical-stage genetic medicines company noted the disease is an after-effect of GUCY2D mutations. Due to photoreceptor function loss, blindness emerges very early in life.
The FDA approval marks a regulatory milestone for the company, demonstrating the therapeutic potential of its technology to address severe childhood blinding conditions.
For comments and feedback contact: editorial@rttnews.com
Health News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.